Cooper Companies (NASDAQ:COO) CEO Albert White III Purchases 10,000 Shares

The Cooper Companies, Inc. (NASDAQ:COO) CEO Albert White III bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were acquired at an average price of $80.80 per share, for a total transaction of $808,000.00. Following the transaction, the chief executive officer directly owned 236,151 shares in the company, valued at approximately $19,081,000.80. This represents a 4.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Cooper Companies Price Performance

NASDAQ COO traded down $0.49 on Tuesday, hitting $81.04. The company had a trading volume of 2,057,390 shares, compared to its average volume of 2,465,645. The company has a market capitalization of $15.88 billion, a PE ratio of 43.11, a PEG ratio of 2.34 and a beta of 1.05. The company’s fifty day moving average price is $73.67 and its 200-day moving average price is $71.65. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $100.24.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the firm posted $1.04 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has authorized a share buyback plan on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

COO has been the subject of several research reports. The Goldman Sachs Group reiterated a “sell” rating and set a $71.00 price objective (up from $64.00) on shares of Cooper Companies in a research note on Monday, December 8th. Mizuho set a $100.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research report on Friday, December 5th. Wells Fargo & Company raised their price objective on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, December 5th. Barclays reaffirmed an “overweight” rating and set a $91.00 target price on shares of Cooper Companies in a research note on Monday, December 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $90.15.

Institutional Trading of Cooper Companies

Several large investors have recently added to or reduced their stakes in COO. Vanguard Group Inc. raised its holdings in shares of Cooper Companies by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock worth $1,725,963,000 after acquiring an additional 421,423 shares during the period. Capital World Investors increased its position in Cooper Companies by 25.7% during the third quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after purchasing an additional 2,159,233 shares during the last quarter. State Street Corp increased its position in Cooper Companies by 1.2% during the second quarter. State Street Corp now owns 8,659,741 shares of the medical device company’s stock worth $616,227,000 after purchasing an additional 104,910 shares during the last quarter. Wellington Management Group LLP raised its stake in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after purchasing an additional 4,756,178 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Cooper Companies by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 5,205,615 shares of the medical device company’s stock valued at $368,893,000 after purchasing an additional 127,907 shares during the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.